Why the study?
Does low diastolic blood pressure increase the risk of adverse cardiovascular outcomes in patients with heart failure with preserved ejection fraction?
Does low diastolic blood pressure increase the risk of adverse cardiovascular outcomes in patients with heart failure with preserved ejection fraction?
Answers are grounded in this paper and cite their sources.
In patients with HFpEF, a low diastolic blood pressure (<70 mm Hg) is associated with an increased risk of adverse cardiovascular outcomes, highlighting the importance of avoiding excessive DBP lowering.
BACKGROUND: It remains unknown whether a low diastolic blood pressure (DBP) increases the risks of cardiovascular events and death in patients with heart failure with preserved ejection fraction (HFpEF). METHODS: We used data from the TOPCAT trial. The primary outcome was a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, or hospitalization for heart failure. Hazard ratios (HRs) were analyzed for DBPs of <60, 60-69, 70-79, and ≥90 mm Hg in comparison with a DBP of 80-89 mm Hg using multivariable Cox proportional hazard models. RESULTS: This study included 3417 patients with HFpEF who had a controlled blood pressure. In the mean follow-up period of 3.0 years, 881 patients experienced at least one confirmed primary outcome event. Compared with patients with a DBP of 80-89 mm Hg, the adjusted HRs for primary outcome events were significantly higher in those with DBPs of <60 mm Hg (HR: 2.19 [95% confidence interval,1.72-2.78]) and 60-69 mm Hg (HR: 1.52 [1.23-1.87]). Similarly, the adjusted HRs for all-cause death, major cardiovascular events, and hospitalization for heart failure, but not stroke, were significantly higher in patients with a DBP of <70 mm Hg. A relationship between a low DBP and adverse outcomes was found in HFpEF patients with a systolic blood pressure of ≥120 mm Hg; however, a low systolic blood pressure with a DBP of ≥70 mm Hg was not associated with these event risks. CONCLUSIONS: A low DBP increased the risks of adverse outcomes in patients with HFpEF.
No takes yet. Share an insight, caveat, or question.
Tsujimoto et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: